Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
Msphere|February 23, 2018
Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits <i>Ex Vivo</i> Lipopolysaccharide-Induced Inflammatory ResponsesChristel Rothe Brinkmann, Jesper Falkesgaard Højen, Thomas Aagaard Rasmussen, et al.
The Journal of Clinical Investigation|February 9, 2016
ART influences HIV persistence in the female reproductive tract and cervicovaginal secretionsRikke Olesen, Michael D Swanson, Martina Kovarova, et al.
Nature Communications|December 13, 2025
HIV-induced sialoglycans on infected CD4+ T cells promote immune evasion from myeloid cell-mediated killingShalini Singh, S M Shamsul Islam, Rui Liu, et al.
The Lancet. HIV|September 24, 2016
Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trialSteffen Leth, Mariane H Schleimann, Sara K Nissen, et al.
Mucosal Immunology|March 11, 2020
Sialylation and fucosylation modulate inflammasome-activating eIF2 Signaling and microbial translocation during HIV infectionLeila B Giron, Ceylan E Tanes, Mariane H Schleimann, et al.
Nature Communications|September 9, 2016
Broad activation of latent HIV-1 in vivoKirston Barton, Bonnie Hiener, Anni Winckelmann, et al.
Journal of Exposure Science & Environmental Epidemiology|August 19, 2021
The size and culturability of patient-generated SARS-CoV-2 aerosolJoshua L Santarpia, Vicki L Herrera, Danielle N Rivera, et al.
AIDS (London, England)|April 2, 2019
Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individualsLine K Vibholm, Christina V Konrad, Mariane H Schleimann, et al.
Heliyon|December 21, 2023
Development and implementation of natural killer cell simultaneous ADCC and direct killing assayMaia M C Bennett-Boehm, Anna R Mahr, Sean T Hartwell, et al.
Journal of Virology|May 20, 2011
One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidatesPaul W Denton, Florence Othieno, Francisco Martinez-Torres, et al.
Pageof 7